文献速递膀胱癌与上尿路尿路上皮癌

高危上尿路尿路上皮癌新辅助化疗应用趋势与肿瘤学结局:多中心回顾性研究

Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
PubMed 文献 · BJU Int · 2021-02-15

该多中心回顾性研究纳入2000至2020年间7家医院289例接受根治性肾输尿管切除术的局部晚期上尿路尿路上皮癌患者,评估新辅助化疗使用趋势及结局。结果显示新辅助化疗使用率从2006-2010年的19%显著增至2016-2020年的79%,且新辅助化疗组病理降期率更高,经IPTW校正的多因素分析显示新辅助化疗显著改善肿瘤学结局,顺铂与卡铂方案间无显著差异。

要点

  • 高危上尿路尿路上皮癌新辅助化疗使用率2010年后显著上升。
  • 新辅助化疗组病理降期率显著高于单纯手术组。
  • 铂类短期新辅助化疗后立即根治性肾输尿管切除术可能不阻碍并潜在改善肿瘤学结局。

核心结论

  • 高危上尿路尿路上皮癌新辅助化疗使用率在2010年后显著增加,铂类短期新辅助化疗后立即根治性肾输尿管切除术可能不阻碍并潜在改善肿瘤学结局。

研究设计与样本

  • 多中心回顾性研究纳入7家医院2000至2020年间289例接受根治性肾输尿管切除术的局部晚期上尿路尿路上皮癌患者(≥cT3或cN+),其中144例接受新辅助化疗后手术,145例单纯手术。

主要发现

  • 新辅助化疗使用率从2006-2010年的19%增至2011-2015年的58%和2016-2020年的79%。
  • 新辅助化疗组病理降期率显著高于单纯手术组。
  • 经IPTW校正的多因素分析显示新辅助化疗组肿瘤学结局显著优于单纯手术组。
  • 在慢性肾脏病≥3期患者中,卡铂为基础的新辅助化疗较单纯手术显著改善肿瘤学结局。
  • 顺铂与卡铂为基础方案间肿瘤学结局无显著差异。

临床怎么用

  • 对于局部晚期上尿路尿路上皮癌患者,可考虑铂类短期新辅助化疗后立即行根治性肾输尿管切除术。
  • 慢性肾脏病≥3期患者可考虑卡铂为基础的新辅助化疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate temporal trends in neoadjuvant chemotherapy (NAC) utilisation and outcomes in patients with locally advanced upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: We included 289 patients from seven hospitals who underwent radical nephroureterectomy (RNU) for locally advanced UTUC (≥cT3 or cN+) between 2000 and 2020. These patients received RNU alone or two to four courses of NAC with either a cisplatin- or carboplatin-based regimen. We evaluated the temporal changes in NAC use and compared the visceral recurrence-free, cancer-specific, and overall survival rates. The effect of NAC on oncological outcomes was examined using multivariate Cox regression analysis with inverse probability of treatment weighting (IPTW) models. RESULTS: Of 289 patients, 144 underwent NAC followed by RNU (NAC group) and 145 underwent RNU alone (Control [Ctrl] group). NAC use increased significantly from 19% (2006-2010), 58% (2011-2015), to 79% (2016-2020). Pathological downstaging was significantly higher in the NAC group than in the Ctrl group. The IPTW-adjusted multivariable analyses showed that NAC significantly improved the oncological outcomes in the NAC group compared with the Ctrl group. Moreover, carboplatin-based NAC significantly improved the oncological outcomes in the NAC group compared with the Ctrl group among patients with chronic kidney disease Stage ≥3. There were no significant differences in oncological outcomes between the cisplatin- and carboplatin-based regimens. CONCLUSIONS: The use of NAC for high-risk UTUC increased significantly after 2010. Platinum-based short-term NAC followed by immediate RNU may not impede and potentially improves oncological outcomes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hamaya T, Hatakeyama S, Tanaka T, et al. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study. BJU Int. 2021. PMID: 33484231. doi:10.1111/bju.15346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。